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Probability of progression
Actinic keratoses (AKs) are thought to be direct precursors of 
squamous cell carcinoma (SCC); however, the rate of this pro-
gression is controversial. Recently, Criscione and colleagues 
examined prospectively collected data from the US Department 
of Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) 
trial in order to estimate the risk of progression from AKs to 
keratinocyte carcinomas (KCs). In 169 subjects, AKs were pho-
tographed every 6 months during a follow-up period of up 
to 6 years. Although the risk of progression from AK to SCC 
was low (0.6% at 1 year and 2.57% at 4 years), the majority 
of SCCs arose from previously diagnosed AKs (65%). In addi-
tion, about 35% of observed basal cell carcinomas arose from 
clinically defined AKs. Thus, the role of AK in the development 
of KCs may be even greater than previously believed. (Cancer 
115:2523–30, 2009)
Cancer by cooperation
Metastatic melanoma is one of the most difficult diseases to treat, 
and no major breakthrough in treatment has been achieved in 
more than 25 years. Thus, knowledge of the genetic and epige-
netic factors involved in melanoma initiation and progression 
is critical. The mutated proto-oncogene Braf V600E is commonly 
detected in melanoma patients in concert with silencing of the 
tumor suppressor PTEN. Dankort and colleagues demonstrated 
that these two genetic alterations cooperate in mice to produce 
melanoma with 100% penetrance and metastases to lymph 
nodes and lungs. These mice exhibited disease mirroring human 
metastatic melanoma; thus, they will be useful in determining 
the genetic events and interactions that are important for its ini-
tiation and progression. In addition, because treatment of these 
mice with inhibitors of downstream effectors (MEK1/2 or mTorc1) 
resulted in tumor prevention or regression, the mice may serve as 
a potent model for testing novel and much-needed therapeutic 
agents in preclinical studies. (Nat Genet 41:544–52, 2009)
Marriage between nanoparticles  
and chemotherapy
Because standard cancer chemotherapies nonspecifically target 
all dividing cells, these regimens often exhibit dose-limiting tox-
icities; therefore, novel strategies to specifically target the tumor 
cells are warranted. Activation of the mitogen-activated protein 
kinase (MAPK) pathway occurs in the majority of human tumors. 
Basu and colleagues recently tethered a selective pharmacologi-
cal inhibitor (PD98059) to a biodegradable polymer (modified 
from polylactic acid glycolic acid) to effectively generate nano-
particles that specifically target the MAPK signaling pathway. 
Treatment of both melanoma and lung carcinoma cells with 
these nanoparticles resulted in inhibition of cell proliferation and 
induction of apoptosis consistent with the inhibition of phospho-
rylation of extracellular signal-related kinase, a member of the 
MAPK pathway. Remarkably, some animals that received these 
particles in conjunction with cisplatin, a first-line chemothera-
peutic agent, exhibited complete tumor regression. This com-
bination could serve as the basis for a multipronged strategy to 
treat cancer. (Proc Natl Acad Sci USA 106:7957–61, 2009)
TEMRA against tuberculosis
Anti–tumor necrosis factor (TNF) antibodies (infliximab) have 
been used successfully to treat severe forms of autoimmune 
diseases such as rheumatoid arthritis, Crohn’s disease, psori-
atic arthritis, and ankylosing spondylitis. Reactivation of latent 
tuberculosis, however, is a clinically significant side effect of 
treatment with anti-TNF antibodies. Using this complication as 
a model for investigation, Bruns and colleagues demonstrated 
that perforin and granulysin were both decreased following anti-
TNF treatment. These factors are components of direct T-cell-
mediated antimicrobial activity against intracellular pathogens 
such as Mycobacterium tuberculosis. In addition, granulysin-
expressing CD8+ cells (TEMRA subset) decreased during anti-TNF 
treatment, and this decrease was associated with decreased 
T-cell-mediated antimicrobial activity, indicating that these 
CD8+ cells are critical for host defense against tuberculosis in 
humans. Future efforts to improve the function of this cell subset 
may be useful for fighting infectious diseases, and reducing the 
effectiveness of these cells may help to decrease the severity of 
autoimmune diseases. (J Clin Invest 119:1167–77, 2009)
Receptors balance immune response
The balance between inflammatory and regulatory immune 
responses determines the progression of many autoimmune 
diseases. Zymosan, a yeast cell-wall derivative that is recognized 
by both Toll-like receptor 2 (TLR2) and dectin-1 and that induces 
both proinflammatory and anti-inflammatory cytokines in den-
dritic cells and macrophages, served as a microbial stimulus to 
investigate mechanisms of immune activation. Manicassamy 
and colleagues demonstrated that zymosan induced retina-
ldehyde dehydrogenase type 2 (Raldh2) in dendritic cells via 
TLR2-mediated activation of the mitogen-activated protein 
kinase pathway. Raldh2 converts vitamin A–derived retinal to 
retinoic acid, which then suppresses proinflammatory cytokine 
production. Thus, TLR2 signaling via retinoic acid metabolism is 
essential for the induction of T regulatory cells and concomitant 
suppression of T helper type (TH1) and TH17 cell autoimmunity. 
On the other hand, zymosan signaling through dectin-1 resulted 
in generation of potent immune responses by TH1 and TH17 cells 
and proinflammatory cytokines. Therefore, two distinct receptors 
that recognize the same pathogenic molecule mediate divergent 
innate and adaptive immune responses to balance the response 
to disease. (Nat Med 15:401–9, 2009)
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